4,5-Dimethyl-1,3-Dioxol-2-One (DMDO) CAS 37830-90-3 Purity >99.0% (GC) Olmesartan Medoxomil Intermediate Factory

Short Description:

Chemical Name: 4,5-Dimethyl-1,3-Dioxol-2-One

Synonyms: DMDO

CAS: 37830-90-3

Purity: >99.0% (GC)  

White to Light Gray to Light Yellow Powder to Crystal

Intermediate of Olmesartan Medoxomil

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 4,5-Dimethyl-1,3-Dioxol-2-One
Synonyms DMDO
CAS Number 37830-90-3
CAT Number RF-PI1877
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C5H6O3
Molecular Weight 114.10
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Light Gray to Light Yellow Powder to Crystal
Purity / Analysis Method >99.0% (GC)    
Melting Point 76.0~80.0℃
Loss on Drying <1.00%
Total Impurities <1.00%
Infrared Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Olmesartan Medoxomil (CAS: 144689-63-4)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

4,5-Dimethyl-1,3-Dioxol-2-One (DMDO) (CAS: 37830-90-3) is used in the preparation of Olmesartan Medoxomil (CAS: 144689-63-4). Olmesartan Medoxomil was launched in the US as Benicar@, an orally administered treatment for hypertension. Olmesartan, is a new selective and competitive nonpeptide angiotensin II type 1 receptor antagonist and potently inhibits the Ang.ll-induced pressor responses. The drug competitively inhibited binding of [125I1]-All to AT1 receptors in bovine adrenal cortical membranes, but had no effect on binding to AT2 receptors in bovine cerebellar membranes. In comparative clinical studies in patients with essential hypertension, Olmesartan reduced sitting cuff diastolic blood pressure significantly more than Losartan, Valdesartan and Ibesartan, while reductions in systolic blood pressure were similar for all treatments. Olmesartan Medoxomil was also shown to reduce blood pressure significantly more effectively than losartan and the ACE inhibitor captopril and as effectively as the pbloker atenolol.

  • Write your message here and send it to us